Working in the arena of protein sequencing, Erisyon is addressing development and commercial utilization of the worlds first single molecule sequencing device anchored in work undertaken at the University of Texas at Austin and having the potential to transform the way diseases are detected, treated, and tracked. With unprecedented sensitivity and scalability for proteomics, the Erisyon approach enables new applications across the variety of medical fields: oncology, diagnostics, plant science, drug development and industrial biology: a viable and efficient tool to discover and diagnose diseases and eradicate cancer among other applications. An area of early focus has been Parkinsons Disease. Anchored in and building out from work developed over the course of the past decade at UTs Center for Systems and Synthetic Biology, Erisyon was founded by a group of technologists and entrepreneurs with the ambition to usher in new discoveries that make the world healthier, safer, and more abundant an obkective that enabled the Michael J Fox Foundation in 2020 to include the firm among its funded entities.
